A chemist at Washington University in St. Louis has found surprisingly tough enzymes in a bacterium that "just says no to acid."
Acid resistance is a valued trait for both pills and human pathogens. The bacterium Acetobacter aceti makes unusually acid-resistant enzymes in spades, which could make the organism a source for new enzyme products and new directions in protein chemistry.
A. aceti has been used for millennia to make vinegar, at least since an indirect reference in the Old Testament Book of Numbers to "vinegar made from wine." But not until recently did anybody study the unusual biochemical features of the organism that allow it to survive and even thrive in very acidic conditions.
Joe Kappock, PhD, assistant professor of chemistry at Washington University in St. Louis couldn't overlook this very promising bacterium.
"The thing that piqued our interest was that this organism has this weird growth habit of making vinegar from ethanol (alcohol), which means it's highly resistant to ethanol, which very few things grow in, and resistant to acetic acid (vinegar), which even fewer things grow in," Kappock said. "Important enzymes in this bug-resist acid in a way almost all organisms cannot, and we're trying to answer the question: 'How is this enzyme different?'"
That answer, Kappock said, could reveal many new important insights.
Kappock discussed his research at the American Chemical Society's Annual Meeting, held Aug. 23-25, 2004, in Philadelphia.
Specifically, Kappock and his research group study the enzyme citrate synthase, one of the oldest enzymes in a cell. Citrate synthase is important because it initiates the citric acid cycle, or Kreb's cycle, a biochemical pathway vitally important for energy production in the cells of organisms simple as bacteria and complex as humans.
There also are a couple of ways Acetobacter could produce industrially applicable information.
"There are people who want to make more stable proteins," said Kappock.
"There are increasing numbers of industrial processes that use enzymes, which are the ultimate green catalyst. The more things we can do with enzymes, the better for the environment, because they have no waste products."
Enzymes already are used in products as diverse as laundry detergents and various medications.
According to Kappock, the more long-range goal is to involve insights from studies of this bacterium with the numerous diseases caused by protein mis-folding. Alzheimer's disease, Lou Gehrig's disease, and possibly even cataracts begin with mis-folded proteins.
"A lot of times a mild acid-mediated unfolding of an enzyme precipitates these kinds of disease," Kappock said. "Insights from these marvelous Acetobacter enzymes might lead to making more stable enzymes or elucidating ways to treat these debilitating diseases. "There are a lot of things that this research could help, but it's at a basic stage now."
Still, the research is promising enough to have been awarded both federal and private funding.
Kappock is a little surprised that relatively few others have studied Acetobacter, given the common and widespread nature of the organism.
"It's literally garden-variety," he said. "Acetobacter clings to plant surfaces in the wild. For example, a big part of winemaking is excluding the grape skins from the wine because the bug lives there."
Plants, microorganisms, and their proteins are the bases for developing valuable drugs.
"Many antibiotics are derived from soil organisms like bacteria that are trying to kill other bacteria," said Kappock.
Fortunately, in the case of Acetobacter, any useful enzymes it may provide should be completely harmless, just as it is to humans (besides ruining their wine).
"I think it's likely going to be a piece of a larger story," Kappock said. "What I'm hoping to get out of it is a better understanding of how proteins work. Our contribution is to find out how a couple of examples work and seeing if we can find general principles."
Source:Washington University in St. Louis
Pioneering Advances in Sterilization: The Future of Infection Control
November 28th 2024Germitec, STERIS, ASP, and Zuno Medical are pioneering sterilization advancements with groundbreaking technologies that enhance SPD workflows, improve patient safety, and redefine infection control standards.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.